Membrane physiology and bioenergetics of the human pathogen Leishmania.
Molecular mechanism of Leishmania differentiation.
Proteomics and transcriptomics of Leishmania development
Amino acid transport in Leishmania parasites
The trypanosomatid parasite of the genus leishmania is the etiological agent of a variety of disease manifestations,
collectively known as Leishmaniasis. Leishmaniasis is prevalent throughout the tropical and sub-tropical regions of Africa,
Asia, the Mediterranean, Southern Europe (old world) and South and Central America (new world). Despite enormous
efforts, it has proved difficult to predict the exact scale of the impact of the Leishmaniasis on public health, since many
cases go unreported or misdiagnosed. It is estimated that approximately 12 million people are currently infected and a
further 367 million are at risk of acquiring leishmaniasis in 88 countries, 72 of which are developing countries and 13 of
them are among the least developed in the world (WHO www site, 1997). Hence linking leishmaniasis to poverty,
economic development and various environmental changes such as deforestation, urbanisation, migration of people into
endemic areas and building of damns etc. The annual incidence rate is estimated to be 1-1.5 million cases of cutaneous
leishmaniasis and 500,000 cases of visceral leishmaniasis, these are the two major clinical types of leishmaniasis (WHO
www site, 1997).